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Abstract
In clinical practice, as well as in other areas where interventions are provided, a sequential
individualized approach to treatment is often necessary, whereby each treatment is adapted
based on the object ′s response. An adaptive intervention is a sequence of decision rules which
formalizes the provision of treatment at critical decision points in the care of an individual. In
order to inform the development of an adaptive intervention, scientists are increasingly interested
in the use of sequential multiple assignment randomized trials (SMART), which is a type of multi-
stage randomized trial where individuals are randomized repeatedly at critical decision points
to a set treatment options. While there is great interest in the use of SMART and in the develop-
ment of adaptive interventions, both are relatively new to themedical and behavioral sciences. As
a result, many clinical researchers will first implement a SMART pilot study (i.e., a small-scale
version of a SMART) to examine feasibility and acceptability considerations prior to conducting
a full-scale SMART study. A primary aim of this paper is to introduce a new methodology to
calculate minimal sample size necessary for conducting a SMART pilot.
1 Introduction
In themedical andbehavioral health sciences, researchers have successfully established evidence-
based treatments for a variety of health disorders. However, even with such treatments, there is
heterogeneity in the type of individuals who respond and do not respond to treatment. Treatment
effects may also vary over time (within the same individual): a treatment that improves outcomes
in the short-run for an individual may not improve outcomes longer-term. Further, certain evi-
dence based treatments may be too expensive to provide to all individuals; in such cases, health
care providers may reserve these treatments for individuals who do not respond to less costly al-
ternatives. The converse is also true: certain treatments are more ideally suited as maintenance
treatments, and may be reserved for individuals who respond to earlier treatments in order to sus-
tain improvements in outcomes. As a result, clinical researchers have recently shown great interest
in developing sequences of treatments that are adapted over time in response to each individual’s
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needs. This approach is promising because it allows clinicians to capitalize on the heterogeneity
of treatment effect. An adaptive intervention offers a way to guide the provision of treatments over
time, leading to such individualized sequence of treatments.
An adaptive intervention [1, 2, 3] is a sequence of decision rules that formalizes the provision of
treatment at critical decision points in the course of care. In other words, an adaptive intervention is
a guideline that can aid clinicians in deciding which treatment to use, for which individuals to use
them, and when to use them. Figure 1 depicts a concrete example of an adaptive intervention for
young children who are initially diagnosed with pediatric anxiety disorder.
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Figure 1: An example adaptive intervention for pediatric anxiety disorder patients
In this example of adaptive intervention, first, clinicians offer the medication sertraline [4] for
initial 12 weeks. If the child does not show an adequate response to it at the end of week 12,
the clinician offers to augment the treatment with a combination of the medication sertraline and
cognitive behavioral therapy [5] for additional 12 weeks. Otherwise the clinician would continue the
sertraline medication for another 12 weeks. In this adaptive intervention, response is defined based
on a measure of improvement, for example, based on a cut-off of five or less on the Clinical Global
Impression-Improvement Scale [6]. Change in the Pediatric Anxiety Rating Scale could also be used to
define response/non-response [7]. An adaptive intervention is also known as an adaptive treatment
strategy [8] or a dynamic treatment regime [9].
Recently, methodologists introduced a specific type of randomized trial design known as a Se-
quential Multiple Assignment Randomized Trials [1, 10, 11] to inform the development of high-quality,
empirically-supported adaptive interventions. A SMART is a type of multi-stage trial where each
subject is randomly (re)assigned to one of various treatment options at each stage. Each stage
corresponds to a critical treatment decision point. Each randomization is intended to address a
critical scientific question concerning the provision of treatment at that stage; together, these help
to inform the development of a high-quality adaptive intervention. Lei et al. [1] reviews a number of
SMART studies in behavioral interventions science. Also, see work by Almirall et al. [10]
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Anexample SMART is provided in Figure 2. This example could be used to develop an adaptive
intervention for children who are diagnosed with pediatric anxiety disorder. At the first stage, there
are two treatment options, sertralinemedication or cognitive behavioral therapy(CBT). Each subject is
randomly assigned to one of the initial treatment options and the assigned treatment is conducted
for the first 12 weeks. At the end of week 12, each subject’s response to the treatment is assessed
based onClinical Global Impression-Improvement Scale [4] and categorized as a responder or as a non-
responder. Based on this, those who do not respond to the initial treatment are again randomly
assigned to one of two secondary treatment options: One is a switch strategy whereby the child
is switched to the stage 1 treatment option they were not offered at first. The second option is
the combination of both sertraline medication and cognitive behavioral therapy(CBT). For those who
responded by the end of 12 weeks, continually initial intervention will be used. As with stage 1,
both stage 2 treatments are provided for 12 weeks.
In a SMART such as the one shown in Figure 2, research outcomes may be collected at the
end of week 24 or throughout, from baseline to week 24. Research outcomes may be continuous,
e.g., Pediatric Anxiety Rating Scale [4] or discrete, e.g., Clinical Global Impression-Improvement Scale
[4]. Note that the measure of response versus non-response at week 12 is not necessarily a research
outcome. It is purely a criterion to categorize participants of the first stage intervention into a group
of responders or that of non-responders.
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Figure 2: An example SMART for pediatric anxiety disorder patients
The SMART study described above can be used to address three key scientific questions in the
development of an adaptive intervention for pediatric anxiety disorder: (1) ’Which treatment to use in
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stage 1, medication or CBT?’ and (2) ’Which tactic is best for non-responders to stage 1 treatment,
switch or augment?’ Both of these questions involve randomized comparisons. Question (1) is
addressed by comparing outcome measures of subgroup A, B and C in the Figure 2 with outcome
measures of subgroupD,E and F in the Figure 2. Question (2) is addressed by comparing subgroup
B and Cwhenmedication sertraline is stage 1 treatment and subgroup E and F when CBT is stage 1
treatment. Lastly, (3) This SMART design could also be used to compare the following four adaptive
interventions contained within it.
1. First, offer sertraline medication for 12 weeks. If the patient does not respond well to initial
medication at the end of week 12, augment by initiating a combination therapy (sertraline
and CBT) for next 12 weeks. Otherwise continue with the medication sertraline for another
12 weeks. (Children in subgroups A and B provided data for this adaptive intervention.)
2. First, offer sertraline medication for 12 weeks. If the patient does not respond well to initial
medication at the end of week 12, switch the treatment to CBT for next 12 weeks. Otherwise
continue with the medication sertraline for another 12 weeks. (Children in subgroups A and
C provided data for this adaptive intervention.)
3. First, offer CBT medication for 12 weeks. If the patient does not respond well to initial med-
ication at the end of week 12, augment by initiating a combination therapy (sertraline and
CBT) for next 12 weeks. Otherwise continue with the medication CBT for another 12 weeks.
(Children in subgroups D and E provided data for this adaptive intervention.)
4. First, offer CBT medication for 12 weeks. If the patient does not respond well to initial medi-
cation at the end of week 12, switch the treatment to sertraline medication for next 12 weeks.
Otherwise continue with the medication CBT for another 12 weeks. (Children in subgroups
D and F provided data for this adaptive intervention.)
Note that the type of design used for SMART study described in Figure 2 is one of the most fre-
quently used design. It has been used in SMART study of adolescent marijuana use [12], cocaine
dependence [13, 14] and youth with conduct disorders [15]. For more recent ongoing SMART studies,
visit the website: http://methodology.psu.edu/ra/smart/projects. For detailed data analysis
method regarding SMART, see the work of Nahum-Shani et al. [11, 16].
Despite the advantages of SMARTs, it is fairly new to clinical research. Therefore, researchers
may have concerns over the feasibility or acceptability of conducting a SMART. Feasibility refers
to the capability of the investigators to perform the SMART and the ability of clinical staff (i.e.,
staff providing treatment) to treat subjects with the adaptive interventions in the SMART. For ex-
ample, psychologists or psychiatrists delivering the stage 1 treatments may have concerns about
the way non-response is defined; it is important to work out these concerns prior to a full-scale
SMART study. Acceptability refers to the tolerability of the adaptive interventions being studied
from the perspectives of study participants, as well as the appropriateness of the decision rules
from the perspective of the clinical staff. For instance, some parents may object to a switch strategy
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(they may, instead, prefer an augmentation or an intensification strategy). If this happens often,
investigators may re-consider the acceptability of the switch strategy prior to conducting a full-
scale SMART. In such cases, researchers may conduct SMART pilot study to resolve feasibility and
acceptability concerns prior to performing the full-scale SMART study.
The design of any study (pilot or full-scale randomized trial) requires researchers to select an
appropriate sample size in order to conduct the study. In full scale randomized trials (including
SMARTs), the sample size is typically determined to ensure sufficient statistical power to detect a
minimally clinically significant treatment effect. For example, in a full scale SMART study, such
as the one shown in Figure 2, the sample size could be determined to provide sufficient power
(e.g., 80%) to detect a minimaly clinically significant treatment effect between any two of the four
embedded adaptive interventions [17].
However, because the primary aim of pilot studies centers on acceptability and feasibility con-
siderations, the sample size for pilot studies is not based on statistical power considerations [18, 19,
20, 21]. For the SMART pilot study, the goal is to examine feasibility and acceptability of conduct-
ing a full-scale trial. One approach for selecting a sample size achieving this is to observe sufficient
number of participants for each subgroup from A to E in Figure 2. This is because each subgroup
corresponds to a particular sequence of treatments and if the investigator does not have an ample
amount of participants in each group, they cannot detect potential problems regarding feasibility
or acceptability of certain sequence of treatments prior to conducting full-scale SMART. The pri-
mary aim of this paper is to introduce a new method which calculates a minimal sample size of
SMART pilot study.
In Section 2, we develop a methodology for calculating a minimal sample size for SMART pilot
studies that are like the pediatric anxiety disorder SMART presented above. In Section 3, we verify
the result using simulations. We also compare our proposed methodology with an pre-existing
method [22]. In Section 4, we extend the method in Section 2 to other types of SMART designs (the
pediatric anxiety SMART described above represents just one type of SMART design). In Section
5, we provide a summary and discussions including areas for future work.
2 A method for calculating the sample size for a SMART pilot study
2.1 The Proposed Approach
In this section, we develop a sample size calculator for SMART pilot studies. We first develop
an approach for the SMART study shown in Figure 2. Note that the method we will provide can
be used in any area of SMART study whose design is identical to the one in Figure 2. Later, in
Section 4, we generalize the method for other types of SMART designs. The approach provides
investigators planning a SMART pilot study a principled way to choose a sample size for the pi-
lot study, such that a minimal number of participants are observed in subgroups A-F in Figure
2. This is important because if the investigators do not observe sufficient number of participants
of one particular sequence of treatments, the investigator cannot judge whether the sequence of
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treatments is actually feasible or can be accepted. For example, suppose that to examine feasibility
and acceptability concerns, an investigator wishes to observe at least three participants in each of
the subgroups A-F in Figure 2: in this case, howmany participants should the investigators recruit
in the study? Because the exact number of non-responders is unknown ahead of the pilot study, a
probabilistic argument is necessary to answer such a question.
To formalize this idea, we first define some notations. Let N denote the total sample size of
the SMART pilot study. For simplicity, we assume N is always a multiple of two; later we discuss
the implications of this. Let m denote the minimum number of participants that an investigator
would like to observe in subgroups A-F. Let qj denote the anticipated rate of non-response to stage
1 treatment where j = SERT or CBT and let q = min(qSERT, qCBT), which will be used as a common
non-response rate; the implications of using the minimum will also be discussed later. Lastly, a
lower bound for the probability of the event that each subgroup will have at least m number of
participants is denoted as k. Note that m, q and k are all provided by the investigator planning the
SMART pilot. Hence, our goal is to provide a formulae for N as a function of m, q and k. More
formally, the goal is to find a smallest Nwhich satisfies
P(all subgroups A-F have at least m participants) > k.
Using our notation, the above is equivalent to
P(MA > m,MB > m,MC > m,MD > m,ME > m andMF > m) > k (1)
where MA stands for the number of participants who fall into subgroup A. MB, MC, MD, ME
andMF are defined in a similar way, respectively. Note thatMA,MB,MC,MD,ME andMF are all
discrete random variables. Next, we re-express (1) as
P(MA > m,MB > m andMC > m) · P(MD > m,ME > m andMF > m) > k. (2)
This is because, by the design of SMART study in Figure 2, any event ofMA,MB andMC is inde-
pendent to that ofMD,ME andMF. Next letMNS denote the number of non-responders out of N2
who were initially assigned to sertraline medication; and, similarly, letMNC denote the number of
non-responders initially assigned to CBT. We first consider the leftmost probability term involv-
ing MA,MB and MC. Notice the event that MB > m and MC > m is equivalent to the event that
MNS > 2m. This is because, once the number of non-responders of sertraline medication is greater
than or equal to 2m, regardless of whetherMNS is odd or even, bothMB andMC would be at least
m due to a block randomization[23] with equal probabilities. For the case, when MNS is odd, we
exclude a participant and proceed the second stage randomization. Therefore, we get
P(MA > m,MB > m andMC > m) = P(MA > m,MNS > 2m) = P
(
N
2
−MNS > m,MNS > 2m
)
.
234
A similar argument can be applied toMD,ME andMF and we have
P(MD > m,ME > m andMF > m) = P(MD > m,MNC > 2m) = P
(
N
2
−MNC > m,MNC > 2m
)
.
Re-expressing (2), our goal is to find the smallest N such that
P
(
N
2
−MNS > m,MNS > 2m
)
· P
(
N
2
−MNC > m,MNC > 2m
)
> k (3)
which is equivalent to,
P
(
N
2
−m >MNS > 2m
)
· P
(
N
2
−m >MNC > 2m
)
> k. (4)
Now note that
MNS =
N/2∑
i=1
Xi, MNC =
N/2∑
i=1
Yi,
where Xi = 1 if the ith participant assigned to sertralinemedication did not respond well or Xi = 0
otherwise. Since the probability of non-response to sertraline is assumed to be q, we have that
Xn has a Bernoulli distribution with success probability q [24]. Similarly, Yn has a Bernoulli dis-
tribution with success probability q (recall the assumption that the probability of non-response
is assumed to be q for both sertraline and CBT). Therefore, MNS and MNC have identical distri-
butions, which we denote by the random variableMq. Further, given the result that the sum of
independent identically distributed Bernoulli random variables has a Binomial distribution [24],
we have that
P
(N
2
−m >Mq > 2m
)2
> k, (5)
whereMq ∼ Binomial
(
N
2 , q
)
or, equivalently,
(
P
(N
2
−m >Mq
)
− P
(
2m− 1 >Mq
))2
> k (6)
holds as well.
As a side note, if we have an odd number of participants, it is impossible to assign an equal
number of participants to each initial intervention. Therefore we set N to be a multiple of 2, this is
because, by the design of our SMART study in Figure 2, there is a block randomization in stage 1
[23]. SettingN as a multiple of 2 allows us to assign equal number of participants to two treatment
options provided at the first stage. Additionally we use a minimum value of the two non-response
rate (qSERT,qCBT) as a common non-response rate(q). This is because, by using a minimum value of
two non-response rates, we will get a robust sample size which satisfies (6).
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2.1.1 Implementation
For fixed values for m, k and q(i.e., provided by the scientists designing a SMART pilot), a
suitable value of N can be found by searching for the smallest N such that (6) holds true. This is
possible because (6) is an inequality with respect toN assuming thatm, k and q are given. This can
be easily accomplished using any computer program capable of calculating upper tail probabilities
for random variables with Binomial distributions(e.g., the pbinom function in R [25]).
Using the implementation outlined above, Table 1 provides values ofN for a range of inputs of
m, k, and q. For example, suppose an investigatorwishes that at least 3(m) participants are observed
in each subgroupwith probability greater than 0.8(k), and assumes that the common non-response
rate is 0.30(q). Based on the Table 1 below, the investigator needs to recruit at least 58 participants
for the SMART pilot study. Note that in this paper, we provide sample sizes for the q values in a
range between 0.2 to 0.8 because for the non-response rate values below 0.2 or above 0.8, as it may
not be feasible to conduct a SMART studies.
Table 1: Minimal sample size of SMART pilot study based on the proposed method
Range of q : 0.20 0.30 0.40 0.50 0.60 0.70 0.80
k = 0.80 m = 3 88 58 42 34 28 32 50
k = 0.80 m = 4 112 74 54 42 36 42 64
k = 0.80 m = 5 136 90 66 52 44 50 76
k = 0.90 m = 3 100 64 48 36 32 38 60
k = 0.90 m = 4 126 82 60 46 40 48 74
k = 0.90 m = 5 150 98 72 56 48 56 86
2.1.2 A Pre-existing Approach
A similar approach to calculate the sample size for SMART pilot studies was first proposed by
Almirall et al. [22]. Their proposal centered on finding the smallest sample size N which satisfies
P(MB > m− 1,MC > m− 1,ME > m− 1 andMF > m− 1) > k.
This differs from our proposed approach, which requires that all six subgroups A-F have at
least m participants with probability greater than k(see (1)). The use of this objective function was
based on the argument that in typical SMART studies, the rate of non-response is often not very
large(i.e less than equal to 0.60). Therefore, in such settings it is highly likely that if the condition
that the number of participants in subgroups B, C, E and F are respectively greater than m − 1
was required, the number of responders in subgroups A and D would also be greater than m− 1,
respectively.
On top of that the pre-existing method had an assumption that the event: MB > m−1&MC >
m − 1 is equivalent to the event: MNS > 2m − 2, which may not be true. Consider the case when
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MNS = 2m− 1. IfMNS = 2m− 1, eitherMB orMC should be m− 1, which violates the condition
given: MB > m − 1 & MC > m − 1. In other words, the condition: MB > m − 1 & MC > m − 1
implies thatMNS > 2m− 2, but not necessarily in the other way around.
Therefore the sample size we get from the pre-existing method will not guarantee that the
investigator would observe at leastm number of people for each subgroupwith probability greater
than k. In next section, we will conduct a simulation study to check validity of the pre-existing
method by comparing the simulation result of the pre-existingmethodwith that of the newmethod
introduced in Section 2.1.
3 Simulation
A simulation experiment is conducted (i) to verify that sample sizes obtained under the pro-
posed approach satisfy equation (6) under a variety of realistic values for m, k and q, and (ii) to
compare the performance of the proposed method with the pre-existing method by Almirall et al.
[22], described above.
The simulation experiment is conducted in the following way for each combination of values
of m, k and q.
1. Firstly, the values m, k and q are used to calculate the minimum suggested sample size N
based on the proposed methodology.
2. Secondly, using this sample sizeN, we simulate the flow of participants through one realiza-
tion of the SMART shown in Figure 2. Specifically, we divide the total sample size(N) by 2.
Then by rbinom function [25] in R, we obtain the number of responders and non-responders
for each pilot SMART simulation, which allows us to get the number of participants in each
of the subgroups A-E.
3. Thirdly, we check if the number of participants in each subgroup is greater than pre-specified
m or not. If the condition is met, we count it as a successful SMART pilot study. This process
is repeated for 10,000 times. In the end, after 10,000 simulations, we obtain the proportion
of successes out of 10,000. This represents an estimate of the left-hand side of expression (1),
which we take it as a true proportion, denoted as ρ, since we are conducting 10,000 times of
Monte Carlo simulation.
4. Lastly, the proportion(ρ) obtained in previous step is compared with a pre-specified lower
bound for the proportion(k). If this proportion(ρ) is greater than k value, we conclude the
sample size obtained from the proposed method is valid. Otherwise, the proposed sample
size is invalid. The Table 2 provides the results of this experiment.
Notice that the number of non-responsers could be an odd number. In this case, we subtract
one from the number of non-responsers and divide by two. Then we use this value to check if it is
greater than m or not. This is to (i) to get a conservative sample size and (ii) to avoid having non
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integer value of participants in each subgroup. If both values are greater than m, then we count
this trial SMART pilot as a successful SMART pilot study.
Table 2: Simulation table of the sample sizes based on the proposed method
Range of q : 0.20 0.30 0.40 0.50 0.60 0.70 0.80
k = 0.80 m = 3 0.807 0.816 0.821 0.860 0.809 0.810 0.815
k = 0.80 m = 4 0.810 0.828 0.814 0.820 0.834 0.844 0.821
k = 0.80 m = 5 0.811 0.825 0.820 0.835 0.838 0.830 0.813
k = 0.90 m = 3 0.911 0.902 0.921 0.903 0.931 0.912 0.910
k = 0.90 m = 4 0.906 0.911 0.921 0.913 0.925 0.920 0.912
k = 0.90 m = 5 0.903 0.906 0.915 0.918 0.926 0.902 0.901
From the simulation result, we can assess if the sample sizes we get from the proposedmethod,
which are in Table 1, are valid or not. For instance, whenm = 3, k = 0.80 and q = 0.30, we need to have
at least 58 participants to conduct a SMART pilot study based on the Table 1. Then, fromTable 2, we
can see that out of 10,000 simulations, roughly in 8,160 (10,000·0.816) times, the condition that there
are 3 or more people in each subgroup is satisfied. Since all the values we get from the simulation
are greater than corresponding k value which is in the left end column, we can say that our new
method developed in previous section is valid.
To see whether the method discussed in Section 2.1 is an improved version, a simulation study
is also conducted, in a same manner, for the pre-existing method [22]. As one can see in Table 3,
pre-existingmethod failed to prove its validity. Again, this is because of the assumptions discussed
in the Section 2.1.2.
Table 3: Simulation table of the sample sizes based on the pre-existing method
Range of q : 0.20 0.30 0.40 0.50 0.60 0.70 0.80
k = 0.80 m = 3 0.633 0.662 0.623 0.616 0.475 0.194 0.000
k = 0.80 m = 4 0.650 0.664 0.650 0.672 0.549 0.353 0.000
k = 0.80 m = 5 0.675 0.691 0.678 0.641 0.592 0.000 0.000
k = 0.90 m = 3 0.790 0.780 0.766 0.803 0.769 0.401 0.000
k = 0.90 m = 4 0.796 0.822 0.818 0.813 0.786 0.000 0.000
k = 0.90 m = 5 0.821 0.820 0.831 0.841 0.806 0.459 0.000
4 Extensions to other SMART pilot studies
Not all SMART studies will be like the type shown in Figure 2. In the SMART in Figure 2, all
non-responders were re-randomized at the second stage regardless of the initial treatment assign-
ment; i.e., re-randomization to second-stage treatment depended only on response/non-response
status. In a second type of commonly-used SMART design, re-randomization at the second stage
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depends on both initial treatment and response/non-response status. In a third type of commonly-
used SMART design, both responders and non-responders are re-randomized at the second stage.
In this section, we extend the methods of Section 2.1 to these two types of SMART designs.
4.1 Re-randomization depends on initial treatment and response status
In this section, we consider SMART studies where re-randomization to second-stage treatment
depends on the choice of initial treatment as well as response/non-response status.
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Figure 3: An example SMART for Children with Autism
As an example, consider the SMART shown in Figure 3. This SMART studywas designed to de-
velop adaptive interventions for improving linguistic and social communication outcomes among
children with autism spectrum disorders who are minimally verbal [26]. Specifically, this SMART
examined the effects of three adaptive interventions involving different provisions of a speech gen-
erating device (SGD; a type of Augmentative and Alternative Communication Interventions). This
SMARTwas facilitated to answer two scientific questions in the context of a behavioral language in-
tervention (BLI) for children with autism [27, 28]. Initially, all children were randomized at stage 1
to BLI versus BLI+SGD for 12 weeks to answer question (1): Is providing SGDmore effective at ini-
tial stage? At the end of week 12, each participant is categorized as a responder or a non-responder
to stage 1 treatment based on 14 measures including: 7 communication variables from natural lan-
guage sample with blinded assessor and 7 communication variables from intervention transcripts
[26]. All responders continued on stage 1 treatment for an additional 12weeks. All non-responders
to BLI+SGD received intensified BLI+SGD. Non-responders to BLI were re-randomized to inten-
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sified BLI versus BLI+SGD to answer question (2): For non-responders to BLI, is providing SGD
with BLI as a rescue intervention more efficacious than intensifying the initial intervention? Total
number of spontaneous communicative utterances, primary outcome of the study, was collected
at week 24 with a follow-up collection at week 36.
The derivation of the sample size formulae for a pilot study of a SMART of this type is similar
to the derivation in Section 2.1. One difference in the notation is that in this SMART design, there
are 5 subgroups, labeled A to E. Our goal is to determine the smallest N which guarantees that
P(all subgroups A-E have at least m participants) > k
Using arguments similar to those used in section 2.1 (see Appendix A), one can show that this
inequality is identical to
[
P
(N
2
−m >Mq
)
− P(2m− 1 >Mq)
]
·
[
P
(N
2
−m >Mq
)
− P(m− 1 >Mq)
]
> k. (7)
Notice that, unlike with the inequality given in equation (6), the left-hand-side of inequality (7)
does not reduce to the square of a probability. This is due to the imbalance in the SMART design
shown in Figure 3(only non-responders to one of the initial treatments are re-randomized) relative
to the design shown in Figure 2(where all non-responders are re-randomized). Given k, q, and m, a
solution forN in expression (7) can be found using an approach that is similar to the one described
earlier to solve expression (6). Table 4 provides a minimal sample size for the type of SMART
designs in Figure 3.
Table 4: Minimal sample size of SMART pilot study for nonverbal children with autism
Range of q : 0.20 0.30 0.40 0.50 0.60 0.70 0.80
k = 0.80 m = 3 78 52 38 30 28 32 50
k = 0.80 m = 4 100 66 48 38 34 42 64
k = 0.80 m = 5 122 80 60 48 42 50 76
k = 0.90 m = 3 90 58 42 34 30 38 60
k = 0.90 m = 4 114 74 54 42 38 48 74
k = 0.90 m = 5 138 90 66 52 46 56 86
See thework of Kilbourne et al. [29], which employs a SMART of this type to enhance outcomes
of a mental disorders program.
4.2 Both responders and non-responders are re-randomized
In this section, we consider a third type of SMART design where both responders and non-
responders are re-randomized. As an example of this type of design, we present a study of indi-
viduals with alcoholic use disorder. The example SMART design is shown in Figure 4. The goal
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of this SMART study, which is reviewed in greater detail in Lei et al. [1], was to develop adap-
tive interventions for individuals with alcoholic use disorders. This SMART was used to answer
three scientific questions regarding the use of naltrexone medication (NTX) [30], an opioid recep-
tor antagonist, for the management and prevention of relapse among individuals with alcohol use
disorder. All participants were provided NTX medication as a stage 1 treatment. Non-response
to NTX was measured on a weekly basis. Participants were randomized initially to two differ-
ent definitions for non-response to NTX–a lenient versus a more stringent definition–to answer
the question (1): What extent of weekly drinking activity is best regarded as non-response? The
lenient definition of non-response was defined as having five or more heavy drinking days per
week, whereas the stringent definition of non-response was defined as having two or more heavy
drinking days per week. Participants identified as non-responders to NTX were re-randomized to
the combination of combined behavioral intervention (CBI) [31, 32],medical management (MM) [33] ver-
sus to the combination of NTX, CBI andMM. This randomization answers the question (2): What
type of treatments would be useful for subjects who do not respond well to NTX? If participants
had not been identified as non-responders by week 8, they were said to be responders to stage 1
intervention. Responders were re-randomized to the NTX versus to the combination of NTX and
telephone disease management (TDM) to answer the question (3): What type of treatments would be
effective for reducing the chance of relapse among people who responded well to NTX? Primary
outcomes included the percentage of heavy drinking days and percentage of drinking days of the
last two months of the study.
R
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Figure 4: An example SMART for alcoholic patients
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The variables m, k, and q are defined as in Section 2.1 (see the Appendix B). In this type of
SMART, there are 8 subgroups, labeled A through H. In addition, randomization occurs both for
responders and non-responders. Our goal is to find a smallest N which satisfies
P(all subgroups A-H have at least m participants) > k
In Appendix B we show that the above equation is true if and only if
[
P
(N
2
− 2m >Mq
)
− P(2m− 1 >Mq)
]2
> k, (8)
As you can see in expression (8), unlike in expression (7), since the design is perfectly symmet-
ric we have two identical probability terms multiplied each other. In addition, unlike expression
(6), instead of m, 2m was subtracted from N2 . This is because, for the type of SMART designs de-
scribed in Figure 4, responders were also randomized. For more detailed explanation on how this
influences the method, see Appendix B. Again, given m, k and q, a solution for N in expression (8)
can be found using an approach that is similar to the one described earlier to solve expression (6).
Table 5 provides a minimal sample size for the type of SMART design in Figure 4.
Table 5: Minimal sample size of SMART pilot study for alcoholic patient
Range of q : 0.20 0.30 0.40 0.50 0.60 0.70 0.80
k = 0.80 m = 3 88 58 42 36 42 58 88
k = 0.80 m = 4 112 74 54 46 54 74 112
k = 0.80 m = 5 136 90 66 56 66 90 136
k = 0.90 m = 3 100 64 48 40 48 64 100
k = 0.90 m = 4 126 82 60 50 60 82 126
k = 0.90 m = 5 150 98 72 60 72 98 150
A number of other SMART studies are similar to the type shown in Figure 4. These stud-
ies include a SMART for developing an adaptive reinforcement-based behavioral intervention for
woman who are pregnant and abusing drugs [34]; a SMART study aimed at developing an adap-
tive intervention involving individual and family-delivered cognitive behavioral therapy among
children with depression; and a SMART designed to develop an adaptive intervention for chil-
dren with autism spectrum disorders who are minimally verbal. All three of these studies are
currently in the field.
5 Discussion
This manuscript presents pilot sample size calculators for three of the most common types
of sequential multiple assignment randomized trial (SMART) designs. As stated in the introduction,
researchers use SMARTs to inform the development of adaptive interventions. More specifically,
SMART designs can be used to address critical scientific questions that need to be answered in
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order to construct high-quality adaptive interventions. Over the last 15 years, SMART designs have
become more popular among clinical and health service researchers. However, some researchers
may have concerns regarding the feasibility of conducting a full scale SMART or the acceptability
of the treatments or adaptive interventions embedded in a SMART design. Such researchers may
choose to conduct a smaller-scale pilot SMART prior to conducting a full-scale SMART. Specifically,
a SMART pilot study is a small scale version of a full scale SMART study, where the primary
purpose is to examine the acceptability and feasibility issues. See the following papers for more
detailed explanations and concrete examples of SMART pilot studies [15, 22, 35].
This paper develops an approach for determining the minimum sample size necessary for con-
ducting a pilot SMART. The number of participants for SMART pilot study should be enough to
address concerns in feasibility and acceptability of full-scale SMART study. The paper introduces
oneway to operationalize this, which is to ensure that each subgroup corresponding to sequence of
treatments to observe someminimumnumber(m) of participants. This approachwas used to select
the sample sizes for two recent SMART pilot studies: 1) SMART for developing an adaptive inter-
vention for adolescent depression [35], 2) SMART for adolescent conduct problems [15]. Further,
the methods are developed for three of the most commonly used types of SMART designs. Finally,
we compare our proposed method with the pre-existing, related method to calculate a sample size
for a SMART pilot [22] and explain how the proposedmethodology is an improvement on the pre-
existing one. In addition, the characteristics of the methodologies developed in this paper were
examined thoroughly via Monte Carlo simulation. Specifically, for each type of SMART design,
10,000 simulation SMART pilot studies were conducted with different combinations of values of
m,k and q via statistical software R. In all possible combinations of m,k and q, the simulation study
supported that the condition imposed on the sample size(N) was met.
The method may be conservative in that, based on the way the rate of non-response is elicited
from the scientist, the method may suggest a sample size that is as large or larger than the sample
size actually needed to meet the constraint. Specifically, our proposed approach elicits the min-
imum value of the non-response rates to first-stage treatments. This was done to minimize the
burden on the investigator of having to guess/provide two non-response rate. In settings where
the two non-response rates differ, using the minimum for both may lead to conservative sample
size requirements, relative to a method which uses both of two different non-response rates. For
the future work, one can possibly develop a new methodology to calculate minimum sample size
for a SMART pilot using two non-response rates. Also one can further investigate, in which cir-
cumstances (i.e. which combinations of m, k and q), a method that uses two non-response rate
values results in substantially small sample size than the method introduced in this paper.
Some suggestions on choosing values for m, k and q are provided in this paragraph. Concern-
ing q: Existing data from previous studies (not necessarily a previous SMART study) are often
used to obtain estimates of q. Typical values of non-response rates for SMART ranges from 0.3 to
0.7. Concerningm: In many cases, we have found that investigators are interested in observing be-
tween 3 and 5 participants for each subgroup of a pilot SMART. Note that for typical pilot studies,
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resources, including the maximum number of participants that could be afforded in a pilot study,
are often limited. And observing between 3 to 5 people for each subgroup is typically enough to
assess feasibility and acceptability issues regarding adaptive interventions. Concerning k: typical
values range from 0.8 to 0.95.
This manuscript provides a way to choose a sample size for a pilot SMART, to examine fea-
sibility and acceptability concerns before conducting a full scale SMART study. Another possible
approach is to choose a sample size so that investigatorsmay observe an estimate of response/non-
response rate with pre-specified amount of precision. Researchers may want to adopt this ap-
proach to estimate non-response rate. By using the estimate of non-response rate, researchers can
implement themethodologies described in the paper. For instance, suppose wewant a sample size
N which allows us to estimate non-response rate(q) within the margin of error of 0.1 with signifi-
cance level 0.05. Then, we estimate q by the proportion of non-responders among total sample(qˆ).
Since the number of non-responders follows a Binomial distribution with parameters q and N
[24, 36], after some calculation, we get N = 100. Note that the above example is just to illustrate
another way to calculate sample size for pilot study. In this way, one can come up with an alterna-
tive way to develop a sample size calculator for SMART pilot study. For more detailed technical
explanation, see Appendix C.
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A Appendix A
Here, we provide a mathematical derivation of equation (7). All the variables used here are
defined in a similar way as in Section 2.1. Recall that what we want to calculate is the smallest N
such that
P(all subgroups A-E have at least m participants) > k
holds. Using mathematical expression, one can write it as
P(MA > m,MB > m,MC > m,MD > m andME > m) > k.
By the independence of the group with behavioral language intervention and the group with both
behavioral language intervention and speech generating device, the above is same as
P(MA > m,MB > m andMC > m) · P(MD > m,ME > m) > k.
Let MNB denote the number of non-responders of behavioral language intervention. Note that the
event: MB > m and MC > m is same as the event: MNB > 2m due to a block randomization with
equal probabilities [23]. Therefore we get
P(MA > m,MB > m andMC > m) = P
(
N
2
−MNB > m,MNB > 2m
)
.
Let MNBS denote the number of non-responders of the initial intervention which involves both
behavioral language intervention and speech generating device. Then,
P(MD > m,ME > m) = P
(
N
2
−MNBS > m,MNBS > m
)
Therefore we find the smallest N, which satisfies
P
(
N
2
−MNB > m,MNB > 2m
)
· P
(
N
2
−MNBS > m,MNBS > m
)
> k,
One can re-write above as
P
(N
2
−Mq > m, Mq > 2m
)
· P
(N
2
−Mq > m, Mq > m
)
> k,
where Mq follows a Binomial distribution with size parameter N2 and probability parameter q.
Re-arrangingMq, we have
P
(N
2
−m >Mq > 2m
)
· P
(N
2
−m >Mq > m
)
> k,
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which is analogous to[
P
(N
2
−m >Mq
)
− P(2m− 1 >Mq)
]
·
[
P
(N
2
−m >Mq
)
− P(m− 1 >Mq)
]
> k.
B Appendix B
Here, we provide a mathematical derivation of equation (8). All the variables used here are
defined in a similar way as in Section 2.1. Recall that what we want to calculate is the smallest N
such that
P(all subgroups A-H have at least m participants) > k
holds. Using mathematical expression, one can write it as
P(MA > m,MB > m,MC > m,MD > m,ME > m,MF > m,MG > m andMH > m) > k.
By design, we know that the group with the lenient definition of non-response and the group with
the stringent definition of non-response are independent. Therefore, the above expression is same
as,
P(MA > m,MB > m,MC > m andMD > m) · P(ME > m,MF > m,MG > m andMH > m) > k
LetMNL denote the number of non-responders for the initial interventionwith lenient definition of
non-response. Similarly we define MNS as the number of non-responders for the initial interven-
tion with stringent definition of non-response. Our next step is to re-express above expression in
terms ofMNL,MNS andN. Note that the event: MC > m andMD is same as the event: MNL > 2m.
In addition, the event: MA > m and MB > m is same as the event: N2 − MNL > 2m. Analogous
arguments can be applied to the event involving subgroup E through H. Therefore we get,
P(MA > m,MB > m,MC > m andMD > m) = P
(
N
2
−MNL > 2m andMNL > 2m
)
and
P(ME > m,MF > m,MG > m andMH > m) = P
(
N
2
−MNS > 2m andMNS > 2m
)
.
Therefore our goal is to find a sample size N, which satisfies
P
(
N
2
−MNL > 2m andMNL > 2m
)
· P
(
N
2
−MNS > 2m andMNS > 2m
)
> k
One can re-write above as
P
(N
2
−Mq > 2m, Mq > 2m
)
· P
(N
2
−Mq > 2m, Mq > 2m
)
> k,
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where Mq follows a Binomial distribution with size parameter N2 and probability parameter q.
Then one can further simplify as
P
(N
2
− 2m >Mq > 2m
)
· P
(N
2
− 2m >Mq > 2m
)
> k,
where the above is equivalent to
[
P
(N
2
− 2m >Mq
)
− P(2m− 1 >Mq)
]2
> k.
C Appendix C
In this section, we provide technical explanation of finding sample size using margin of error.
Recall that the number of non-responders follows a Binomial distribution with parameters q andN
[24, 36]. One can show that qˆ, a proportion of non-responders among total sample, is an unbiased
estimate of q and its variance and standard deviation are below [37]:
Var(qˆ) = q(1− q)
N
⇒ sd(qˆ) =
√
q(1− q)
N
.
Then the goal is to find a sample size N which satisfies
2 ·
√
q(1− q)
N
= 0.1.
However, since we do not know the true value of q, we instead use 12 as a value of q to find conser-
vative sample size of N [36, 38]. By solving above formula after plugging in 12 to q, we have
1√
N
= 0.1⇒ N = 100.
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